Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

120.83 +0.07 (+0.06%)
Streaming Delayed Price Updated: 10:13 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
65 66 Next >
Pfizer, BioNTech Say Three-Dose Covid Vaccine Is 80% Effective In Children Under 5
Pfizer tested a three-dose vaccine in nearly 1,700 children. 
Via Investor's Business Daily
Morning Brief: Top Financial Stories Dominating on Monday, May 23
CNBC US Announces Asia Economic Deal To Strengthen Foothold, Check China 
Via Benzinga
European Regulator Approves AstraZeneca's COVID-19 shot As Booster
Via Benzinga
Pfizer-BioNTech's Third COVID-19 Vaccine Shot Shows 80% Efficacy In Youngest Children
Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine 
Via Benzinga
Where BioNTech Stands With Analysts
Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings: 
Via Benzinga
Why BioNTech Stock Is Rising Today
BioNTech SE (NASDAQ: BNTX) shares are trading higher Monday after the company reported financial results and reaffirmed its 2022 outlook. 
Via Benzinga
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
From Pfizer Inc.
Via Business Wire
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Friday, May 20
Reuters 
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
CDC Recommends Pfizer/BioNTech COVID-19 Booster Shots For Kids Aged 5-11 Years
Via Benzinga
Cramer Shares His Thoughts On BioNTech, Vertex Energy And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Veru Inc. (NASDAQ: VERU) is "up a great deal … we caught it much lower." 
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
FDA Gives Green Signal To Pfizer/BioNTech's COVID-19 Booster For Kids 5-11 Years
Via Benzinga
Pfizer Retakes A Key Line — And Drags BioNTech, Moderna With It
The FDA decision also prodded BioNTech and Moderna stocks higher. 
Via Investor's Business Daily
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Tuesday, May 17
Reuters KKR To Scoop This Power Company At 36% Premium 
Via Benzinga
FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 16
CNBC Volkswagen CEO Shares Ambitious EV Ambitions For US Market 
Via Benzinga
Pfizer/BioNTech COVID-19 Vaccine's European Delivery Takes Backseat To Help Booster Campaign
Via Benzinga
Johnson & Johnson Stock: A Rare Bright Spot in the Market
JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility. 
Via InvestorPlace
Biden Says US Ready To Share COVID-19 Vaccine Related Technology
Via Benzinga
White House Says Currently No Plans To Share COVID-19 Shots With North Korea Battling Outbreak
The Biden administration says it currently has no plans to share COVID-19 vaccines with North Korea, Reuters reported citing White House press secretary Jen Psaki. However, it supported providing aid... 
Via Benzinga
Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review
Elon Musk put his Twitter deal "on hold" but says he's "still committed" to it. 
Via Investor's Business Daily
Cboe's Weekly Market Recap: May 2nd To May 6th
Photo by m. on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Should Biotech Be On The Critical List?
The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation. 
Via Talk Markets
Novavax's 22% Post-Earnings Plunge: 5 Factors That Took Toll
Novavax, Inc. (NASDAQ: NVAX) shares slumped 22.27% after-hours on Monday, reacting to its quarterly financial report. 
Via Benzinga
BNTX Stock Treks Higher on BioNTech’s Vaccine Sales
BNTX stock is climbing on Monday after BioNTech reported better-than-expected results. The company credits Covid-19 vaccine innovation. 
Via InvestorPlace
Cash Appears To Be King As Investors Sell Stocks, Bonds, And Commodities
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.